Osteo Complex - Clinical Trials

I Product Info I Ingredients
I Recommended Use
I Clinical Trials
I Research Brief
I References

osteocmplg

 

Order this item

Indication: osteoporosis prophylaxis, inflammatory and degenerative changes in the joints, bone fractures, nail and hair fragility.

Actions: strengthens bones, ligaments and joints, the source of bioavailable calcium and manganese, prevents osteoporosis, reduces joint pain and inflammation, helps to rehabilitate the joint cartilage, normalizes the production of synovial fluid, strengthens teeth, nails and hair.

Ingredients (per 1 tablet):

Vitamin C (as ascorbic acid) - 10 mg, Calcium (as dicalcium phosphate) - 100 mg, Manganese (as manganese sulfate) - 0.3 mg, Glucosamine HCL – 250 mg, Proprietary Blend - 58.5  mg:  Boswellia extract (Boswellia serrata)(gum exude), Bromelain (from Ananas comosus), Nettle (Urtica dioica) leaf.

Low USA domestic & international shipping

  

Osteo Complex - Clinical Trials:

The randomized, placebo-controlled, double-blind clinical study of 212 patients with knee osteoarthritis showed a greater decrease in pain in the group taking 1200 mg of glucosamine in comparison with placebo group. (9)

Clinical trial to determine the effectiveness of glucosamine versus ibuprofen has showed the benefits of glucosamine. Patients were separated into two groups and administered either 1500 mg of glucosamine or 1200 mg of ibuprofen. The patients who received the Glucosamine treatment reported less pain than those taking ibuprofen, as well as better mobility and less swelling. Those taking the glucosamine also reported less adverse side effects than those taking ibuprofen. (10)

To compare the efficacy, safety and tolerability of Boswellia serrata extract (BSE) in osteoarthritis (OA) knee with valdecoxib, a selective COX-2 inhibitor. Materials and Methods: In a randomized, prospective, open-label, comparative study the efficacy, safety and tolerability of BSE was compared with valdecoxib in 66 patients of OA of knee for six months. The patients were assessed by WOMAC scale at baseline and thereafter at monthly interval till 1 month after drug discontinuation. Antero-posterior radiographs of affected knee joint were taken at baseline and after 6 months. Results: In BSE group the pain, stiffness, difficulty in performing daily activities showed statistically significant improvement with two months of therapy which even lasted till one month after stopping the intervention. In valdecoxib group the statistically significant improvement in all parameters was reported after one month of therapy but the effect persisted only as long as drug therapy continued. Three patients from BSE group and two from valdecoxib group complained of acidity. One patient from BSE group complained of diarrhea and abdominal cramps. Conclusion: BSE showed a slower onset of action but the effect persisted even after stopping therapy while the action of valdecoxib became evident faster but waned rapidly after stopping the treatment. (11)